Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Entecavir demonstrated superior virologic and biochemical benefits over lamivudine and
adefovir. The investigators evaluated the effect of entecavir combined Hepatitis B immune
globulin (HBIG) with lamivudine or adefovir or both combined HBIG in Chinese liver
transplantation patients with Hepatitis B Virus (HBV) related diseases.